Actively Recruiting
Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)
Led by Vastra Gotaland Region · Updated on 2025-07-09
40
Participants Needed
1
Research Sites
343 weeks
Total Duration
On this page
Sponsors
V
Vastra Gotaland Region
Lead Sponsor
S
Sahlgrenska University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a single centre Window-of-Opportunity trial investigating the efficacy and feasibility of short term imatinib in patients with newly diagnosed triple negative breast cancer (TNBC) planned for surgery, with tumours ≥ 15 mm, any status in the axilla when neoadjuvant treatment not is considered as an option. The primary aim is to determine the proportion of patients that converts to estrogen receptor (ER) positive breast cancer in the removed breast cancer tissue at surgery.
CONDITIONS
Official Title
Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed invasive primary triple negative breast cancer with tumor size 15 mm or larger, any lymph node status
- Age 18 years or older
- Triple negative subtype defined by ER- and PR-negative status (less than 10% staining by immunohistochemistry) and HER2-negative status
- No previous systemic treatment for triple negative breast cancer
- No concurrent anti-cancer treatment (bisphosphonates allowed)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Normal organ function as specified by blood counts and liver, kidney tests
- Negative pregnancy test within 8 days before starting imatinib for patients of childbearing potential
- Female patients of childbearing potential must agree to use effective contraception during treatment and for at least 90 days after last dose
- Ability to swallow oral medication
- Ability to understand and comply with the protocol and provide informed consent
You will not qualify if you...
- Patients suitable for neoadjuvant treatment
- Concurrent breast cancer treatment within 14 days before registration
- Inability to follow study procedures
- Medical conditions that could interfere with treatment or compliance
- Pregnancy or breastfeeding
- Concurrent malignancies requiring therapy (except non-invasive or in situ carcinoma)
- Known HIV infection
- Known active Hepatitis B or Hepatitis C infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Barbro Linderholm
Gothenburg, Sweden, 41345
Actively Recruiting
Research Team
B
Barbro K Linderholm, MD, PhD
CONTACT
E
Elisabeth Kapocs
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here